{"success":true,"data":{"pressRelease":{"id":"165254","rtpr_id":"nNFC58J4Sb-20261009","ticker":"TLT","exchange":"","all_tickers":["TLT"],"title":"Theralase(R) to Present at ThinkEquity Conference","author":"Newsfile Corp","published_at":"2026-10-09T11:00:19.280Z","article_body":"Toronto, Ontario--(Newsfile Corp. - October 9, 2026) - Theralase®\nTechnologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the\n\"Company\"), a clinical-stage pharmaceutical company dedicated to the research\nand development of proprietary Energy-Activated Small Molecules (\"EASMs\") for\nthe safe and effective destruction of various cancers, bacteria and viruses,\nis pleased to announce that the Company has been invited to present at the\n2026 ThinkEquity Conference in New York.\n\nThinkEquity is a boutique investment bank that has collectively financed over\n$50 billion of public and private capital raises, restructurings, mergers and\nacquisitions. The annual ThinkEquity Conference brings together institutional\ninvestors, accredited investors and industry executives with private and\npublic emerging growth companies, featuring corporate presentations across\nnumerous sectors. The 2026 ThinkEquity Conference is expected to feature 85\ncompany presentations, more than 750 attendees and more than 750 one-on-one\ninvestor meetings.\n\nRoger DuMoulin-White, B.Sc., P.Eng., Pro.Dir., President and Chief Executive\nOfficer of Theralase®, will deliver a corporate presentation in the\nbiotechnology track providing an overview on the Company's proprietary EASM\ntechnology platform, clinical development programs and upcoming corporate\nobjectives.\n\nThe presentation is expected to include information on:\n*\nThe Phase II clinical study evaluating intravesical light-activated Ruvidar®\nin patients diagnosed with Bacillus Calmette-Guérin (\"BCG\")-Unresponsive\nNon-Muscle Invasive Bladder Cancer (\"NMIBC\") Carcinoma In-Situ (\"CIS\")\n*\nRegulatory strategy for Ruvidar® in Canada and the United States\n*\nDevelopment of radiation-activated intravenous Rutherrin® for the treatment\nof: Glioblastoma Multiforme (\"GBM\"), Non-Small Cell Lung Cancer (\"NSCLC\") and\nMuscle Invasive Bladder Cancer (\"MIBC\")\n*\nDevelopment of topical Ruvidar® for the treatment of Herpes Simplex Virus\nType 1 (\"HSV-1\") cold sores\n\nTheralase® management will also participate in scheduled meetings with\ninvited conference participants.\n\nRoger DuMoulin-White, President and Chief Executive Officer of Theralase®,\nstated, \"The ThinkEquity Conference provides Theralase® an important\nopportunity to engage directly with the US-based investment community as we\nprepare for Health Canada and FDA review of our bladder cancer clinical data,\nclinical development of our proprietary EASM technology platform for numerous\ncancers and clinical development of topical Ruvidar® for cold sores. We look\nforward to discussing our clinical progress, commercialization strategies and\nmarketing opportunities of Ruvidar® and Rutherrin® with investors and\nindustry participants, upon regulatory approval.\"\n\nAbout Theralase® Technologies Inc.\n\nTheralase® is a clinical-stage pharmaceutical company dedicated to the\nresearch and development of proprietary EASMs for the safe and effective\ndestruction of various cancers, bacteria and viruses.\n\nThe Company's lead clinical program is focused on evaluating intravesical\nlight-activated Ruvidar® for the treatment of BCG-Unresponsive NMIBC CIS. In\naddition, Theralase® is developing Rutherrin® for radiation-activated\nintravenous administration for the treatment of GBM, NSCLC and MIBC, as well\nas topical Ruvidar® for the treatment of HSV-1 cold sores.\n\nAdditional information is available at www.theralase.com and www.sedarplus.ca\n\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nForward-Looking Statements\n\nThis news release contains forward-looking statements and forward-looking\ninformation (collectively, \"FLS\") within the meaning of applicable Canadian\nsecurities laws. Such statements; include, but are not limited to statements\nregarding the Company's proposed development plans with respect to\nenergy-activated small molecules and their drug formulations. FLS may be\nidentified by the use of the words \"may, \"should\", \"will\", \"anticipates\",\n\"believes\", \"plans\", \"expects\", \"estimate\", \"potential for\" and similar\nexpressions; including, statements related to the current expectations of the\nCompany's management regarding future research, development and\ncommercialization of the Company's Energy-Activated Small Molecules (\"EASMs\");\ntheir drug formulations; preclinical research; clinical studies and regulatory\napprovals.\n\nThese statements involve significant risks, uncertainties and assumptions;\nincluding, the ability of the Company to fund and secure regulatory approvals\nto successfully complete various clinical studies in a timely fashion and\nimplement its commercial development plans. Other risks to the Company\ninclude: successful commercialization of its EASMs and drug formulations;\naccess to sufficient capital to fund the Company's operations on terms that\nare commercially favorable to the Company or at all; the safety and\neffectiveness of the Company's EASMs and formulations against the diseases\ntested in its clinical studies; the failure to comply with the terms of\nlicense agreements with third parties and as a result lose the right to use\nkey intellectual property in its business; the ability to protect its\nintellectual property; the timing and success of submission, acceptance and\napproval of regulatory filings. Many of these factors that will determine\nactual results are beyond the Company's ability to control or predict.\n\nReaders should not unduly rely on these FLS, which are not a guarantee of\nfuture performance. There can be no assurance that FLS will prove to be\naccurate, as such FLS involve known and unknown risks, uncertainties and other\nfactors which may cause actual results or future events to differ materially\nfrom the FLS.\n\nAlthough the FLS contained in the press release are based upon what management\ncurrently believes to be reasonable assumptions, the Company cannot assure\nprospective investors that actual results, performance or achievements will be\nconsistent with these FLS.\n\nAll FLS are made as of the date hereof and are subject to change. Except as\nrequired by law, the Company assumes no obligation to update such FLS.\n\nFor investor information on the Company, please feel to reach out Investor\nInquiries - Theralase Technologies\n(https://api.newsfilecorp.com/redirect/EZbz7I2RJa).\n\nFor More Information:\n1.866.THE.LASE (843.5273)\n416.699.LASE (5273)\nwww.theralase.com\n\nKristina Hachey, CPA\nChief Financial Officer X 224\nkhachey@theralase.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/318110","article_body_html":"","raw_payload":{"data":{"id":"nNFC58J4Sb-20261009","title":"Theralase(R) to Present at ThinkEquity Conference","author":"Newsfile Corp","ticker":"TLT","created":"2026-10-09T11:00:19.280Z","tickers":["TLT"],"exchange":"","article_body":"Toronto, Ontario--(Newsfile Corp. - October 9, 2026) - Theralase®\nTechnologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the\n\"Company\"), a clinical-stage pharmaceutical company dedicated to the research\nand development of proprietary Energy-Activated Small Molecules (\"EASMs\") for\nthe safe and effective destruction of various cancers, bacteria and viruses,\nis pleased to announce that the Company has been invited to present at the\n2026 ThinkEquity Conference in New York.\n\nThinkEquity is a boutique investment bank that has collectively financed over\n$50 billion of public and private capital raises, restructurings, mergers and\nacquisitions. The annual ThinkEquity Conference brings together institutional\ninvestors, accredited investors and industry executives with private and\npublic emerging growth companies, featuring corporate presentations across\nnumerous sectors. The 2026 ThinkEquity Conference is expected to feature 85\ncompany presentations, more than 750 attendees and more than 750 one-on-one\ninvestor meetings.\n\nRoger DuMoulin-White, B.Sc., P.Eng., Pro.Dir., President and Chief Executive\nOfficer of Theralase®, will deliver a corporate presentation in the\nbiotechnology track providing an overview on the Company's proprietary EASM\ntechnology platform, clinical development programs and upcoming corporate\nobjectives.\n\nThe presentation is expected to include information on:\n*\nThe Phase II clinical study evaluating intravesical light-activated Ruvidar®\nin patients diagnosed with Bacillus Calmette-Guérin (\"BCG\")-Unresponsive\nNon-Muscle Invasive Bladder Cancer (\"NMIBC\") Carcinoma In-Situ (\"CIS\")\n*\nRegulatory strategy for Ruvidar® in Canada and the United States\n*\nDevelopment of radiation-activated intravenous Rutherrin® for the treatment\nof: Glioblastoma Multiforme (\"GBM\"), Non-Small Cell Lung Cancer (\"NSCLC\") and\nMuscle Invasive Bladder Cancer (\"MIBC\")\n*\nDevelopment of topical Ruvidar® for the treatment of Herpes Simplex Virus\nType 1 (\"HSV-1\") cold sores\n\nTheralase® management will also participate in scheduled meetings with\ninvited conference participants.\n\nRoger DuMoulin-White, President and Chief Executive Officer of Theralase®,\nstated, \"The ThinkEquity Conference provides Theralase® an important\nopportunity to engage directly with the US-based investment community as we\nprepare for Health Canada and FDA review of our bladder cancer clinical data,\nclinical development of our proprietary EASM technology platform for numerous\ncancers and clinical development of topical Ruvidar® for cold sores. We look\nforward to discussing our clinical progress, commercialization strategies and\nmarketing opportunities of Ruvidar® and Rutherrin® with investors and\nindustry participants, upon regulatory approval.\"\n\nAbout Theralase® Technologies Inc.\n\nTheralase® is a clinical-stage pharmaceutical company dedicated to the\nresearch and development of proprietary EASMs for the safe and effective\ndestruction of various cancers, bacteria and viruses.\n\nThe Company's lead clinical program is focused on evaluating intravesical\nlight-activated Ruvidar® for the treatment of BCG-Unresponsive NMIBC CIS. In\naddition, Theralase® is developing Rutherrin® for radiation-activated\nintravenous administration for the treatment of GBM, NSCLC and MIBC, as well\nas topical Ruvidar® for the treatment of HSV-1 cold sores.\n\nAdditional information is available at www.theralase.com and www.sedarplus.ca\n\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nForward-Looking Statements\n\nThis news release contains forward-looking statements and forward-looking\ninformation (collectively, \"FLS\") within the meaning of applicable Canadian\nsecurities laws. Such statements; include, but are not limited to statements\nregarding the Company's proposed development plans with respect to\nenergy-activated small molecules and their drug formulations. FLS may be\nidentified by the use of the words \"may, \"should\", \"will\", \"anticipates\",\n\"believes\", \"plans\", \"expects\", \"estimate\", \"potential for\" and similar\nexpressions; including, statements related to the current expectations of the\nCompany's management regarding future research, development and\ncommercialization of the Company's Energy-Activated Small Molecules (\"EASMs\");\ntheir drug formulations; preclinical research; clinical studies and regulatory\napprovals.\n\nThese statements involve significant risks, uncertainties and assumptions;\nincluding, the ability of the Company to fund and secure regulatory approvals\nto successfully complete various clinical studies in a timely fashion and\nimplement its commercial development plans. Other risks to the Company\ninclude: successful commercialization of its EASMs and drug formulations;\naccess to sufficient capital to fund the Company's operations on terms that\nare commercially favorable to the Company or at all; the safety and\neffectiveness of the Company's EASMs and formulations against the diseases\ntested in its clinical studies; the failure to comply with the terms of\nlicense agreements with third parties and as a result lose the right to use\nkey intellectual property in its business; the ability to protect its\nintellectual property; the timing and success of submission, acceptance and\napproval of regulatory filings. Many of these factors that will determine\nactual results are beyond the Company's ability to control or predict.\n\nReaders should not unduly rely on these FLS, which are not a guarantee of\nfuture performance. There can be no assurance that FLS will prove to be\naccurate, as such FLS involve known and unknown risks, uncertainties and other\nfactors which may cause actual results or future events to differ materially\nfrom the FLS.\n\nAlthough the FLS contained in the press release are based upon what management\ncurrently believes to be reasonable assumptions, the Company cannot assure\nprospective investors that actual results, performance or achievements will be\nconsistent with these FLS.\n\nAll FLS are made as of the date hereof and are subject to change. Except as\nrequired by law, the Company assumes no obligation to update such FLS.\n\nFor investor information on the Company, please feel to reach out Investor\nInquiries - Theralase Technologies\n(https://api.newsfilecorp.com/redirect/EZbz7I2RJa).\n\nFor More Information:\n1.866.THE.LASE (843.5273)\n416.699.LASE (5273)\nwww.theralase.com\n\nKristina Hachey, CPA\nChief Financial Officer X 224\nkhachey@theralase.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/318110"},"type":"article","timestamp":"2026-10-09T11:00:19.384650255Z","server_sent_at_ms":1791543619384},"received_at":"2026-10-09T11:00:19.435Z","source_url":"https://www.newsfilecorp.com/release/318110"},"analysis":{"id":"153651","press_release_id":"165254","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Theralase Technologies has been invited to present at the 2026 ThinkEquity Conference in New York, with CEO Roger DuMoulin-White delivering the corporate presentation in the biotechnology track.\n\nThe presentation will cover the Phase II Ruvidar study in BCG-Unresponsive NMIBC CIS, regulatory strategy in Canada and the US, and development programs for Rutherrin in GBM, NSCLC and MIBC, plus topical Ruvidar for HSV-1 cold sores.\n\nManagement will also hold one-on-one meetings with institutional and accredited investors as the company prepares for Health Canada and FDA review of its bladder cancer data.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor-conference appearance ahead of anticipated regulatory review -- no new data."},"keyFigures":{},"quotedText":"The ThinkEquity Conference provides Theralase® an important opportunity to engage directly with the US-based investment community as we prepare for Health Canada and FDA review of our bladder cancer clinical data","namedEntities":{"people":[{"name":"Roger DuMoulin-White","role":"President and CEO"},{"name":"Kristina Hachey","role":"CFO"}],"products":["Ruvidar","Rutherrin"],"companies":[{"name":"Theralase Technologies Inc.","ticker":"TLT","relationship":"filer"},{"name":"ThinkEquity","relationship":"conference host / investment bank"}],"dollarAmounts":[{"amount":"$50 billion","context":"capital raises collectively financed by ThinkEquity"}]},"materialImpact":{"score":1,"reasoning":"Routine announcement of a conference presentation with no new clinical, regulatory, or financial results disclosed."},"tickerRelevance":{"others":[],"primary":"TLT"},"globalImportance":8,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-presentation","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Theralase Technologies has been invited to present at the 2026 ThinkEquity Conference in New York, with CEO Roger DuMoulin-White delivering the corporate presentation in the biotechnology track.\n\nThe presentation will cover the Phase II Ruvidar study in BCG-Unresponsive NMIBC CIS, regulatory strategy in Canada and the US, and development programs for Rutherrin in GBM, NSCLC and MIBC, plus topical Ruvidar for HSV-1 cold sores.\n\nManagement will also hold one-on-one meetings with institutional and accredited investors as the company prepares for Health Canada and FDA review of its bladder cancer data.","key_figures":{},"named_entities":{"people":[{"name":"Roger DuMoulin-White","role":"President and CEO"},{"name":"Kristina Hachey","role":"CFO"}],"products":["Ruvidar","Rutherrin"],"companies":[{"name":"Theralase Technologies Inc.","ticker":"TLT","relationship":"filer"},{"name":"ThinkEquity","relationship":"conference host / investment bank"}],"dollarAmounts":[{"amount":"$50 billion","context":"capital raises collectively financed by ThinkEquity"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-09T11:00:23.584Z","global_importance":8,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-presentation","issuerAuthored":true}},"durationMs":4140,"modelName":"glm-5.3-flashx"}}